FINANCINGS
Amag Pharmaceuticals Inc. priced $175 million worth of 2.5 percent convertible senior notes due in 2019.
Argos Therapeutics Inc. raised $45 million from its initial public offering (IPO).
Auspex Pharmaceuticals Inc. completed its IPO of 8.05 million shares of common stock at $12 each.
Bioblast Pharma Ltd. is seeking to raise $37.5 million from an IPO.
Biodelivery Sciences International Inc. sold $60 million worth of shares in a registered direct offering.
Clarus Ventures LLC disclosed in an SEC filing that it plans to raise a $375 million fund.
Concert Pharmaceuticals Inc. priced its IPO and raised $84 million.
Egalet Corp. closed its IPO of 4.2 million shares at $12 per share.
Eleven Biotherapeutics inc. closed its IPO of 5.75 million shares of common stock at $10 per share.
Five Prime Therapeutics Inc. closed a public offering generating gross proceeds of $43.1 million.
Flexion Therapeutics Inc. priced its IPO of 5 million shares of common stock at $13 each.
Genocea Biosciences Inc. closed its IPO of 5.5 million shares at $12 each.
Halozyme Therapeutics Inc. closed its public offering for net proceeds of approximately $107.8 million.
Idera Pharmaceuticals Inc. closed its public offering for gross proceeds of approximately $40 million.
Ironwood Pharmaceuticals Inc. closed a public offering for net proceeds of approximately $190.4 million.
Macrogenics Inc. priced a public offering selling 1.8 million of the shares for $65.7 million.
Melinta Therapeutics Inc. raised $70 million to support its delafloxacin new drug application.
Nephrogenex Inc. priced its IPO of 3.1 million shares at $12 apiece for a raise of $37.2 million.
PDL BioPharma Inc. closed its offering of $300 million in convertible senior unsecured notes.
Plandai Biotechnology Inc. said Lincoln Park Capital Fund LLC has committed to invest up to $15.3 million.
PTC Therapeutics Inc. priced a public offering for $109.7 million, selling 4.4 million shares at $24.50 each.
Puma Biotechnology Inc. raised $138 million from a public offering of shares at $122.50 each.
UniQure B.V. closed its initial public offering of 5.4 million ordinary shares at $17 each.
Voyager Therapeutics Inc. raised $45 million in a Series A financing round.
DEALS
Agenus Inc. completed its acquisition of 4-Antibody AG.
Apricus Biosciences Inc. signed an agreement with Recordati SpA to market Vitaros (alprostadil).
Mallinckrodt plc is acquiring Cadence Pharmaceuticals Inc. for approximately $1.3 billion.
Mast Therapeutics Inc. has agreed to acquire Aires Pharmaceuticals Inc.
Merck & Co. Inc. and Samsung Bioepis Co. Ltd. have expanded their collaboration.
Retrophin Inc. signed an agreement to acquire Manchester Pharmaceuticals LLC for $62.5 million.
. . . AND MORE
Alcobra Ltd. submitted an investigational new drug application to start a phase III trial with MG01CI in adults with attention deficit disorder.
Celgene Corp. said the board of directors voted to recommend a 2-for-1 stock split.
Sigma-Tau Pharmaceuticals Inc. is developing a live organism used to repopulate patients’ gastrointestinal tracks.
The Cardiovascular and Renal Drugs Advisory Committee voted against approving The Medicines Co.’s cangrelor antiplatelet drug.